undamentalytics Newsletter

Gagnon Neil: insider trades

10% owner at 3 companies we cover. 48 open-market purchases and 2 sales not made under a pre-set plan, reported from January 15, 2015 to May 2, 2024.

Would copying Gagnon Neil’s purchases have beaten the S&P 500?

Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on January 16, 2015 into $47,952 by November 2, 2026, +14.3% a year. The copy held shares only 25% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $16,087, +4.1% a year (the S&P 500 held throughout made $45,534, +13.8% a year). Beta against the index was 0.14. Twelve months after each report, the average purchase was +0.1% against the S&P 500 (median −20.1%), and 13% beat it: within what luck alone would produce (p = 0.22 over 4 years). Measured from the trade date, the insider’s own timing, the average was +0.2%. After their sales, the shares moved −10.6% against the index over 12 months on average (a negative figure means selling was the right call); 50% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 201520172019202120232025 $48.0k$45.5k$16.1k
Copying Gagnon NeilS&P 500, same days investedS&P 500, held throughout $10,000 copying Gagnon Neil’s open-market purchases from January 16, 2015, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+14.3%
S&P 500, same days invested
+4.1% (held throughout +13.8%)
Time in shares
25%
Sharpe ratio (S&P 500)
0.53 (0.70)
Biggest drop (S&P 500)
−52% (−34%)
Market sensitivity (beta)
0.14
Purchases copied
23

Trade by trade

Gagnon Neil: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 23 −15.3% −21.9% 22% 4 0.40 0.71 No reliable evidence
Purchases, 6 months after the report 23 −2.7% −11.6% 22% 4 1.16 0.33 No reliable evidence
Purchases, 12 months after the report 23 +0.1% −20.1% 13% 4 1.55 0.22 No reliable evidence
Purchases, 12 months after the trade 23 +0.2% −21.8% 13% 4 1.61 0.21 No reliable evidence
Sales, 3 months after the report 2 −8.0% −8.0% 100% 2 — — Not enough years
Sales, 12 months after the report 2 −10.6% −10.6% 50% 2 — — Not enough years
Sales, 12 months after the trade 2 −3.1% −3.1% 50% 2 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Caredx, Inc. CDNA —261January 15, 2015November 2, 2018
Power Solutions International, Inc. PSIX —150August 17, 2022May 2, 2024
Ameresco, Inc. AMRC —71November 4, 2015December 13, 2016

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
May 2, 2024April 30, 2024 PSIX Purchase $155,236 not yetnot yetnot yet
April 29, 2024March 25, 2024 PSIX Purchase $17,862 not yetnot yetnot yet
March 22, 2024March 20, 2024 PSIX Purchase $10,784 not yetnot yetnot yet
March 15, 2024March 1, 2024 PSIX Purchase $13,634 not yetnot yetnot yet
March 1, 2024February 29, 2024 PSIX Purchase $48,885 not yetnot yetnot yet
May 26, 2023May 24, 2023 PSIX Purchase $20,241 not yetnot yetnot yet
January 11, 2023January 9, 2023 PSIX Purchase $16,095 not yetnot yetnot yet
January 9, 2023January 5, 2023 PSIX Purchase $17,616 not yetnot yetnot yet
November 30, 2022November 28, 2022 PSIX Purchase $16,569 not yetnot yetnot yet
November 22, 2022November 21, 2022 PSIX Purchase $15,000 not yetnot yetnot yet
November 21, 2022November 17, 2022 PSIX Purchase $13,998 not yetnot yetnot yet
November 17, 2022November 15, 2022 PSIX Purchase $61,712 not yetnot yetnot yet
September 27, 2022September 26, 2022 PSIX Purchase $10,994 not yetnot yetnot yet
September 21, 2022September 20, 2022 PSIX Purchase $17,730 not yetnot yetnot yet
August 17, 2022August 15, 2022 PSIX Purchase $27,621 not yetnot yetnot yet
November 2, 2018October 31, 2018 CDNA Sale $2,937,603 −7.6%−38.6%−26.9%
April 30, 2018April 26, 2018 CDNA Purchase $95,481 +24.2%+163.8%+180.6%
October 6, 2017October 5, 2017 CDNA Purchase $42,568 +14.1%+304.4%+293.3%
September 8, 2017September 7, 2017 CDNA Purchase $19,813 not yetnot yetnot yet
August 30, 2017August 28, 2017 CDNA Purchase $59,411 not yetnot yetnot yet
August 28, 2017August 24, 2017 CDNA Purchase $102,685 not yetnot yetnot yet
June 27, 2017June 23, 2017 CDNA Purchase $69,432 not yetnot yetnot yet
May 2, 2017April 28, 2017 CDNA Purchase $13,453 not yetnot yetnot yet
March 20, 2017January 20, 2017 CDNA Purchase $225,103 not yetnot yetnot yet
December 13, 2016December 9, 2016 AMRC Sale $242,481 −8.5%+17.4%+20.7%
September 23, 2016September 21, 2016 CDNA Purchase $714,511 not yetnot yetnot yet
July 14, 2016July 12, 2016 AMRC Purchase $51,386 −3.4%+18.7%+21.2%
April 18, 2016April 14, 2016 CDNA Purchase $374,744 not yetnot yetnot yet
March 9, 2016March 7, 2016 AMRC Purchase $78,582 not yetnot yetnot yet
November 18, 2015November 17, 2015 AMRC Purchase $40,739 −21.9%−16.2%−16.9%
November 17, 2015November 16, 2015 AMRC Purchase $17,290 −22.7%−18.7%−19.8%
November 9, 2015November 6, 2015 AMRC Purchase $151,141 −20.8%−26.6%−29.8%
November 6, 2015November 5, 2015 AMRC Purchase $236,600 −18.4%−27.2%−26.9%
November 4, 2015November 2, 2015 AMRC Purchase $32,000 −17.5%−26.9%−24.4%
October 1, 2015September 29, 2015 CDNA Purchase $38,625 not yetnot yetnot yet
September 9, 2015September 4, 2015 CDNA Purchase $482,212 −13.8%−45.1%−48.7%
June 8, 2015June 5, 2015 CDNA Purchase $36,985 +24.7%−18.6%−25.0%
April 20, 2015April 16, 2015 CDNA Purchase $69,722 +36.9%−16.9%−18.0%
March 23, 2015March 17, 2015 CDNA Purchase $40,175 +5.9%−19.7%−26.8%
March 2, 2015February 27, 2015 CDNA Purchase $25,748 −21.9%−28.8%−14.9%
February 9, 2015February 6, 2015 CDNA Purchase $33,019 −32.4%−23.7%−29.7%
February 6, 2015February 5, 2015 CDNA Purchase $863,268 −32.0%−22.4%−32.6%
February 5, 2015February 4, 2015 CDNA Purchase $223,937 −33.6%−29.7%−29.5%
February 4, 2015February 2, 2015 CDNA Purchase $165,685 −32.0%−32.6%−31.4%
February 2, 2015January 29, 2015 CDNA Purchase $108,424 −28.2%−33.1%−28.9%
January 27, 2015January 23, 2015 CDNA Purchase $592,997 −34.8%−26.4%−13.7%
January 22, 2015January 21, 2015 CDNA Purchase $346,976 −29.0%−13.7%−20.0%
January 20, 2015January 16, 2015 CDNA Purchase $107,778 −32.1%−20.0%−20.1%
January 16, 2015January 15, 2015 CDNA Purchase $251,471 −33.6%−19.3%−11.4%
January 15, 2015January 13, 2015 CDNA Purchase $864,921 −30.9%−20.1%−21.8%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Gagnon Neil traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.